Platinum-based chemotherapy drugs work by entering cancer cells and physically binding to their DNA, creating structural damage that prevents the cells from copying themselves and ultimately triggers their death. Three platinum agents dominate modern oncology: cisplatin, carboplatin, and oxaliplatin. Each carries the same platinum core but differs in its chemical shell, which changes how fast it acts, which cancers it treats best, and what side effects it causes. Together, these drugs are estimated to be part of treatment regimens for roughly half of all patients who receive chemotherapy, making them among the most widely used anticancer compounds in the world.
An Accidental Discovery
Platinum chemotherapy owes its existence to a biology experiment that had nothing to do with cancer. In 1965, physicist Barnett Rosenberg was studying how electric fields affect bacterial growth. He noticed that Escherichia coli bacteria placed between platinum electrodes stopped dividing but kept growing, ballooning to roughly 300 times their normal size. Rosenberg eventually traced the effect not to the electric field itself but to a platinum compound, cis-diamminedichloroplatinum(II), leaching from the electrodes into the solution. If this compound could halt bacterial cell division, he reasoned, it might do the same to tumor cells. That hypothesis proved correct, and cisplatin entered clinical trials in the early 1970s before gaining FDA approval in 1978.1PubMed. Platinum anticancer drugs. From serendipity to rational design
Getting Inside Cancer Cells
A platinum drug injected into your bloodstream has to cross a cancer cell’s outer membrane before it can do any damage. Researchers have found that these drugs hitch a ride on the same transport system the body uses to move copper. A protein called copper transporter 1, or CTR1, sits on the cell surface and normally ferries copper ions inside. Because platinum and copper bind to sulfur-containing molecules in similar ways, CTR1 also pulls cisplatin, carboplatin, and oxaliplatin into the cell.2PubMed Central. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs This is more than a curiosity: clinical studies have shown that tumors expressing higher levels of CTR1 accumulate more platinum and tend to respond better to treatment.3PubMed Central. Role of copper transporters in platinum resistance
Once inside the cell, the platinum compound undergoes a chemical activation. In the case of cisplatin, chloride ions that were holding the molecule stable get replaced by water molecules, making the platinum atom highly reactive. This “aquated” form is what actually attacks DNA. Carboplatin and oxaliplatin go through a similar activation step, though their different chemical groups make it happen more slowly, which partly explains their milder side-effect profiles.
How Platinum Damages DNA
The activated platinum atom latches onto DNA by forming strong bonds with certain nitrogen atoms on the DNA bases, particularly guanine. When it grabs two spots on the same DNA strand, it creates an intrastrand crosslink; when it grabs bases on opposite strands, it creates an interstrand crosslink.4PubMed. Interstrand cross-links of cisplatin induce striking distortions in DNA Both types physically warp the double helix, bending and unwinding it in ways the cell’s machinery cannot easily read past.
These distortions set off alarm bells inside the cell. Repair proteins rush to the site and attempt to fix the damage. If the damage is too extensive to repair, the cell activates a self-destruct program called apoptosis. This process involves a cascade of signaling proteins, including the well-known tumor suppressor p53, which acts as a checkpoint: if the DNA is too badly mangled, p53 tips the balance toward cell death rather than letting a damaged cell keep dividing.5PubMed. Platinum-DNA interactions and subsequent cellular processes controlling sensitivity to anticancer platinum complexes Cancer cells divide faster than most normal cells, which gives them less time to repair platinum-induced damage before they need to copy their DNA again. That timing mismatch is a big part of why platinum drugs preferentially kill tumors.
Three Drugs, Three Personalities
Cisplatin, carboplatin, and oxaliplatin share a platinum core but behave differently in the body because of the chemical groups surrounding that core. Cisplatin is the most reactive of the three: it activates quickly once injected, which makes it potent but also makes it harder on healthy tissue. Carboplatin swaps cisplatin’s chloride groups for a bulkier cyclobutanedicarboxylate group, which slows down its activation and generally causes less kidney damage and nausea. Oxaliplatin carries a large diaminocyclohexane ring, which changes the shape of the DNA crosslinks it forms and gives it activity against cancers that resist cisplatin and carboplatin.
Studies of how these drugs interact with biological molecules confirm that their different chemical shells lead to different binding behaviors. While cisplatin and carboplatin tend to target the same sites on proteins, oxaliplatin can bind to additional sites, which may contribute to its distinct spectrum of anticancer activity and its unique side-effect profile.6PubMed. Interactions of carboplatin and oxaliplatin with proteins: Insights from X-ray structures and mass spectrometry studies of their ribonuclease A adducts
Which Cancers Platinum Drugs Treat
Cisplatin remains the backbone of treatment for testicular cancer, where it helped transform cure rates from dismal to above 90 percent for early-stage disease. It is also used as first-line therapy for ovarian, bladder, head and neck, cervical, and certain lung cancers, as well as some lymphomas and sarcomas.7PubMed Central. Cisplatin-Based Chemotherapy of Human Cancers Its broad activity across so many tumor types is unusual among chemotherapy agents.
Carboplatin largely replaced cisplatin in ovarian cancer treatment because it is easier on the kidneys and causes less nausea, while still delivering comparable survival benefits. Doctors dose carboplatin differently from most chemotherapy drugs: instead of basing the dose on body surface area, they use a formula that accounts for kidney function, aiming for a specific drug exposure level in the blood. This pharmacokinetic dosing approach allows for more precise and individualized treatment.8PubMed. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study
Oxaliplatin found its niche in colorectal cancer, where cisplatin and carboplatin have limited effectiveness. Combined with fluorouracil and leucovorin in the FOLFOX regimen, oxaliplatin became a standard treatment for both advanced and early-stage colon cancer.9PubMed Central. Role of oxaliplatin in the treatment of colorectal cancer A landmark trial showed that adding oxaliplatin to fluorouracil-based chemotherapy after colon cancer surgery improved three-year disease-free survival from about 73 percent to 78 percent.10PubMed. Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
Side Effects Depend on the Drug
Because platinum drugs do not exclusively target cancer cells, they also damage healthy tissue, particularly in organs where cells turn over rapidly or where the drugs tend to accumulate. Each of the three agents has a somewhat different toxicity profile.
Cisplatin is notorious for causing severe nausea and vomiting; it is considered the most emetogenic cancer drug in common use. It is also hard on the kidneys, and aggressive hydration with intravenous saline before and after infusion is the standard strategy to protect kidney function.11PubMed Central. Prevention of cisplatin nephrotoxicity A protective agent called amifostine can further reduce kidney damage in some patients.
Carboplatin trades kidney toxicity for blood-count suppression. Its main dose-limiting side effect is thrombocytopenia, a drop in platelets that increases the risk of bleeding. It still causes nausea, though less intensely than cisplatin.12PubMed. Comparative adverse effect profiles of platinum drugs
Oxaliplatin’s signature side effect is peripheral neuropathy, which comes in two distinct forms. The acute version happens during or shortly after infusion and shows up as tingling, numbness, or extreme sensitivity to cold in the hands, throat, and mouth. Touching a cold surface or drinking a cold beverage can trigger sharp pain or muscle spasms. Research suggests this acute sensitivity results from oxalate, a byproduct of oxaliplatin breakdown, interfering with ion channels in nerve cells.13Frontiers in Pain Research. Pathological Mechanisms and Preventive Strategies of Oxaliplatin-Induced Peripheral Neuropathy Animal studies have shown that oxaliplatin also reshapes the expression of potassium and other ion channels in pain-sensing neurons, fundamentally altering how they respond to cold temperatures.14PubMed Central. Oxaliplatin-induced cold hypersensitivity is due to remodelling of ion channel expression in nociceptors The chronic form of oxaliplatin neuropathy develops with cumulative doses and involves lasting numbness and tingling in the fingers and toes that can persist for months or even years after treatment ends. This chronic form is caused by the platinum compound itself accumulating in nerve tissue.
Hearing Loss from Cisplatin
One of cisplatin’s more distressing side effects is ototoxicity, or damage to the inner ear that can cause permanent hearing loss. The drug triggers a buildup of reactive oxygen species in the delicate hair cells of the cochlea, which are responsible for converting sound waves into nerve signals.15PubMed Central. Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies High-frequency hearing usually goes first, so patients may initially notice trouble understanding speech in noisy rooms or difficulty hearing birdsong or alarm tones.
Research has identified a specific uptake mechanism behind this toxicity. Organic cation transporters on kidney and inner-ear cells actively pump cisplatin into those tissues, concentrating the drug where it does the most collateral harm. In animal studies, mice lacking these transporters showed no signs of hearing damage and only mild kidney injury after cisplatin treatment. When normal mice were given cimetidine, a common heartburn drug that blocks these transporters, they were protected from hearing loss and partially protected from kidney damage.16The American Journal of Pathology. Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective Interventions This finding has spurred interest in developing protective co-treatments, though translating animal results to clinical use is still ongoing work.
Why Tumors Become Resistant
Platinum drugs often work well initially, but many tumors eventually stop responding. Resistance develops through several pathways, and often multiple mechanisms operate simultaneously in the same tumor.
The most straightforward route is reduced drug uptake. If a cancer cell dials down its production of CTR1, less platinum gets inside and less DNA damage occurs. At the same time, cells can pump platinum back out more efficiently by ramping up copper efflux transporters called ATP7A and ATP7B.17PubMed Central. Translocation of platinum anticancer drugs by human copper ATPases ATP7A and ATP7B The net result is lower intracellular platinum concentration and weaker drug effect.
Tumors can also resist platinum by getting better at repairing the DNA damage it causes. One key player is a repair enzyme called ERCC1, which snips out platinum-damaged sections of DNA so they can be replaced with clean copies. Tumors that overexpress ERCC1 can essentially undo the drug’s work before it triggers apoptosis. In non-small-cell lung cancer, for example, high baseline levels of ERCC1 have been linked to poorer response and survival in patients treated with cisplatin.18PubMed. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer A third resistance mechanism involves defects in the apoptosis pathway itself: if the cell’s self-destruct program is broken, even extensive DNA damage may not kill it.
Platinum Drugs and Radiation
Cisplatin is frequently given alongside radiation therapy for cancers of the head and neck, cervix, and lung. The two treatments work together in a way that is more than additive. Laboratory studies have shown that cisplatin interferes with one of the cell’s main mechanisms for repairing the type of DNA breaks that radiation causes, called nonhomologous end joining. By blocking this repair pathway, cisplatin makes radiation-induced breaks more lethal to cancer cells.19PubMed Central. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining This radiosensitization effect has been confirmed across multiple cell types, including treatment-resistant cell populations.20PubMed Central. Cisplatin radiosensitizes radioresistant human mesenchymal stem cells
In practice, concurrent chemoradiation with cisplatin has become a standard-of-care approach for several cancers. The tradeoff is that side effects are generally worse than either treatment alone, because both the drug and the radiation affect the same mucosal tissues. Managing the increased nausea, mouth sores, and difficulty swallowing that come with the combination is a significant part of supportive care during treatment.
Long-Term Effects After Treatment Ends
Surviving cancer treated with platinum drugs brings its own set of medical concerns. The best-studied population is testicular cancer survivors, many of whom were treated with cisplatin-based regimens in their twenties or thirties and then lived for decades. Reviews of long-term outcomes in these survivors have found elevated risks of cardiovascular disease, kidney impairment, persistent nerve damage, ongoing hearing loss, low testosterone, fertility problems, and pulmonary toxicity.21PubMed Central. Long-term toxicity of cisplatin in germ-cell tumor survivors
The cardiovascular risk is particularly worth knowing about. Cisplatin appears to damage the lining of blood vessels, and studies have found higher rates of high blood pressure, elevated cholesterol, and metabolic syndrome in long-term survivors compared to the general population. Because these patients are often young men who would not otherwise be screened for heart disease, oncologists increasingly recommend ongoing cardiovascular monitoring as part of survivorship care. Hearing loss tends to be cumulative and irreversible, so baseline hearing tests before treatment and regular follow-up audiometry help catch changes early enough to adapt, even if they cannot be reversed.
What Comes After Current Platinum Drugs
Despite decades of effort, only three platinum drugs have achieved widespread clinical use worldwide: cisplatin, carboplatin, and oxaliplatin. Thousands of other platinum compounds have been synthesized and tested, but most failed due to excessive toxicity, poor solubility, or no clear advantage over existing options. Research is now exploring several new strategies to improve on the current drugs.
One approach involves platinum(IV) prodrugs. These are inert compounds that only become active once they reach the tumor environment and get reduced to their active platinum(II) form. Because they are stable in the bloodstream, they cause less collateral damage to healthy tissue during transit and can potentially be taken as pills rather than intravenous infusions. Another direction uses nanoparticle delivery systems, including polymer-based carriers, gold nanoparticles, and carbon nanostructures, to shuttle platinum drugs preferentially into tumor tissue. Photoactivatable platinum compounds represent yet another frontier: these remain harmless until exposed to light, allowing clinicians to activate the drug only in the area being treated.22PubMed Central. The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
Platinum Chemotherapy in Veterinary Medicine
Platinum drugs are not exclusive to human oncology. Dogs, in particular, receive cisplatin and carboplatin for bone cancers and other solid tumors, with response patterns broadly similar to those in humans. Cats, however, are a striking exception. Cisplatin is fatally toxic to cats even at standard therapeutic doses. All cats in early toxicity studies became severely short of breath and died within 48 to 96 hours of receiving the drug, with postmortem examination revealing massive fluid accumulation in the chest and severe lung swelling.23PubMed. Cisplatin toxicity in cats This species-specific pulmonary toxicity has no direct parallel in humans or dogs and remains one of the more dramatic examples of how the same drug can behave completely differently across species. Carboplatin, which is gentler in humans as well, can be used in cats at carefully adjusted doses, making it the only platinum agent available for feline cancer treatment.